{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:13:49Z","timestamp":1793106829411,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Blood-based biomarkers of immune checkpoint inhibitors (ICIs) response in patients with nasopharyngeal carcinoma (NPC) are lacking, so it is necessary to identify biomarkers to select NPC patients who will benefit most or least from ICIs. The absolute values of lymphocyte subpopulations, biochemical indexes, and blood routine tests were determined before ICIs-based treatments in the training cohort (<jats:italic>n<\/jats:italic>\u2009=\u2009130). Then, the least absolute shrinkage and selection operator (Lasso) Cox regression analysis was developed to construct a prediction model. The performances of the prediction model were compared to TNM stage, treatment, and Epstein\u2013Barr virus (EBV) DNA using the concordance index (C-index). Progression-free survival (PFS) was estimated by Kaplan\u2013Meier (K\u2013M) survival curve. Other 63 patients were used for validation cohort. The novel model composed of histologic subtypes, CD19<jats:sup>+<\/jats:sup> B cells, natural killer (NK) cells, regulatory T cells, red blood cells (RBC), AST\/ALT ratio (SLR), apolipoprotein B (Apo B), and lactic dehydrogenase (LDH). The C-index of this model was 0.784 in the training cohort and 0.735 in the validation cohort. K\u2013M survival curve showed patients with high-risk scores had shorter PFS compared to the low-risk groups. For predicting immune therapy responses, the receiver operating characteristic (ROC), decision curve analysis (DCA), net reclassifcation improvement index (NRI) and integrated discrimination improvement index (IDI) of this model showed better predictive ability compared to EBV DNA. In this study, we constructed a novel model for prognostic prediction and immunotherapeutic response prediction in NPC patients, which may provide clinical assistance in selecting those patients who are likely to gain long-lasting clinical benefits to anti-PD-1 therapy.<\/jats:p>","DOI":"10.1007\/s00262-023-03626-w","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T06:01:49Z","timestamp":1705557709000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A novel model for predicting prognosis and response to immunotherapy in nasopharyngeal carcinoma patients"],"prefix":"10.1007","volume":"73","author":[{"given":"Ya-Xian","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Yu","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Yuan","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run-Kun","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,18]]},"reference":[{"issue":"6","key":"3626_CR1","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1158\/1055-9965.EPI-20-1702","volume":"30","author":"ET Chang","year":"2021","unstructured":"Chang ET et al (2021) The evolving epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomark Prev 30(6):1035\u20131047","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"10192","key":"3626_CR2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","volume":"394","author":"YP Chen","year":"2019","unstructured":"Chen YP et al (2019) Nasopharyngeal carcinoma. Lancet 394(10192):64\u201380","journal-title":"Lancet"},{"issue":"5","key":"3626_CR3","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/cncr.27853","volume":"119","author":"WY Wang","year":"2013","unstructured":"Wang WY et al (2013) Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein\u2013Barr virus DNA levels. Cancer 119(5):963\u2013970","journal-title":"Cancer"},{"issue":"11","key":"3626_CR4","first-page":"549","volume":"33","author":"CM Tsang","year":"2014","unstructured":"Tsang CM et al (2014) Epstein\u2013Barr virus infection and persistence in nasopharyngeal epithelial cells. Chin J Cancer 33(11):549\u2013555","journal-title":"Chin J Cancer"},{"issue":"13","key":"3626_CR5","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1158\/0008-5472.CAN-16-2706","volume":"77","author":"D Huang","year":"2017","unstructured":"Huang D et al (2017) Epstein\u2013Barr virus-induced VEGF and GM-CSF drive nasopharyngeal carcinoma metastasis via recruitment and activation of macrophages. Cancer Res 77(13):3591\u20133604","journal-title":"Cancer Res"},{"issue":"11","key":"3626_CR6","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199509143331103","volume":"333","author":"R Pathmanathan","year":"1995","unstructured":"Pathmanathan R et al (1995) Clonal proliferations of cells infected with Epstein\u2013Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med 333(11):693\u2013698","journal-title":"N Engl J Med"},{"issue":"5","key":"3626_CR7","volume":"6","author":"Q Zhu","year":"2017","unstructured":"Zhu Q et al (2017) Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes. Oncoimmunology 6(5):e1312240","journal-title":"Oncoimmunology"},{"key":"3626_CR8","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221096214","author":"JY Xu","year":"2022","unstructured":"Xu JY et al (2022) Current status and advances of immunotherapy in nasopharyngeal carcinoma. Ther Adv Med Oncol. https:\/\/doi.org\/10.1177\/17588359221096214","journal-title":"Ther Adv Med Oncol"},{"issue":"12","key":"3626_CR9","doi-asserted-by":"crossref","first-page":"e003790","DOI":"10.1136\/jitc-2021-003790","volume":"9","author":"Y Yang","year":"2021","unstructured":"Yang Y et al (2021) Efficacy, safety, and biomarker analysis of camrelizumab in previously treated recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN study). J Immunother Cancer 9(12):e003790","journal-title":"J Immunother Cancer"},{"issue":"9","key":"3626_CR10","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s41591-021-01444-0","volume":"27","author":"HQ Mai","year":"2021","unstructured":"Mai HQ et al (2021) Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nat Med 27(9):1536\u20131543","journal-title":"Nat Med"},{"issue":"7718","key":"3626_CR11","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","volume":"560","author":"G Chen","year":"2018","unstructured":"Chen G et al (2018) Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 560(7718):382\u2013386","journal-title":"Nature"},{"issue":"8","key":"3626_CR12","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1093\/annonc\/mdx190","volume":"28","author":"MF Sanmamed","year":"2017","unstructured":"Sanmamed MF et al (2017) Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. Ann Oncol 28(8):1988\u20131995","journal-title":"Ann Oncol"},{"issue":"2","key":"3626_CR13","doi-asserted-by":"crossref","first-page":"e000678","DOI":"10.1136\/jitc-2020-000678","volume":"8","author":"A Keegan","year":"2020","unstructured":"Keegan A et al (2020) Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC. J Immunother Cancer 8(2):e000678","journal-title":"J Immunother Cancer"},{"issue":"24","key":"3626_CR14","doi-asserted-by":"crossref","first-page":"6212","DOI":"10.1158\/1078-0432.CCR-18-0386","volume":"24","author":"R Raja","year":"2018","unstructured":"Raja R et al (2018) Early reduction in ctDNA predicts survival in patients with lung and bladder cancer treated with durvalumab. Clin Cancer Res 24(24):6212\u20136222","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3626_CR15","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s40425-019-0649-2","volume":"7","author":"M Tamminga","year":"2019","unstructured":"Tamminga M et al (2019) Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors. J Immunother Cancer 7(1):173","journal-title":"J Immunother Cancer"},{"issue":"22","key":"3626_CR16","doi-asserted-by":"crossref","first-page":"10262","DOI":"10.7150\/thno.49047","volume":"10","author":"S Xing","year":"2020","unstructured":"Xing S et al (2020) An ultrasensitive hybridization chain reaction-amplified CRISPR-Cas12a aptasensor for extracellular vesicle surface protein quantification. Theranostics 10(22):10262\u201310273","journal-title":"Theranostics"},{"issue":"1","key":"3626_CR17","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ijrobp.2006.07.012","volume":"67","author":"CW Twu","year":"2007","unstructured":"Twu CW et al (2007) Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 67(1):130\u2013137","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"3626_CR18","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1158\/1078-0432.CCR-09-2796","volume":"16","author":"WY Wang","year":"2010","unstructured":"Wang WY et al (2010) Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic\/recurrent nasopharyngeal carcinoma. Clin Cancer Res 16(3):1016\u20131024","journal-title":"Clin Cancer Res"},{"issue":"7","key":"3626_CR19","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1200\/JCO.20.02712","volume":"39","author":"FH Wang","year":"2021","unstructured":"Wang FH et al (2021) Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02). J Clin Oncol 39(7):704\u2013712","journal-title":"J Clin Oncol"},{"issue":"3","key":"3626_CR20","volume":"5","author":"JY Xu","year":"2022","unstructured":"Xu JY et al (2022) Association of plasma Epstein\u2013Barr virus DNA with outcomes for patients with recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 immunotherapy. JAMA Netw Open 5(3):e220587","journal-title":"JAMA Netw Open"},{"issue":"4","key":"3626_CR21","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41423-020-00565-9","volume":"18","author":"ST Paijens","year":"2021","unstructured":"Paijens ST et al (2021) Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol Immunol 18(4):842\u2013859","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"3626_CR22","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","volume":"175","author":"M Sade-Feldman","year":"2018","unstructured":"Sade-Feldman M et al (2018) Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175(4):998-1013.e20","journal-title":"Cell"},{"issue":"17","key":"3626_CR23","doi-asserted-by":"crossref","first-page":"9414","DOI":"10.3390\/ijms22179414","volume":"22","author":"HJ An","year":"2021","unstructured":"An HJ, Chon HJ, Kim C (2021) Peripheral blood-based biomarkers for immune checkpoint inhibitors. Int J Mol Sci 22(17):9414","journal-title":"Int J Mol Sci"},{"issue":"2","key":"3626_CR24","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.cell.2020.09.001","volume":"183","author":"BY Nabet","year":"2020","unstructured":"Nabet BY et al (2020) Noninvasive early identification of therapeutic benefit from immune checkpoint inhibition. Cell 183(2):363-376.e13","journal-title":"Cell"},{"issue":"3","key":"3626_CR25","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.annonc.2019.11.010","volume":"31","author":"R Barroso-Sousa","year":"2020","unstructured":"Barroso-Sousa R et al (2020) Prevalence and mutational determinants of high tumor mutation burden in breast cancer. Ann Oncol 31(3):387\u2013394","journal-title":"Ann Oncol"},{"issue":"10","key":"3626_CR26","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle A et al (2020) Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 21(10):1353\u20131365","journal-title":"Lancet Oncol"},{"key":"3626_CR27","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ejca.2020.10.017","volume":"145","author":"I Gataa","year":"2021","unstructured":"Gataa I et al (2021) Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy. Eur J Cancer 145:221\u2013229","journal-title":"Eur J Cancer"},{"issue":"1","key":"3626_CR28","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s40425-019-0770-2","volume":"7","author":"S Chen","year":"2019","unstructured":"Chen S et al (2019) Mechanisms regulating PD-L1 expression on tumor and immune cells. J Immunother Cancer 7(1):305","journal-title":"J Immunother Cancer"},{"issue":"6","key":"3626_CR29","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","volume":"18","author":"DB Doroshow","year":"2021","unstructured":"Doroshow DB et al (2021) PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol 18(6):345\u2013362","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"3626_CR30","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/annonc\/mdz390","volume":"30","author":"N Tarazona","year":"2019","unstructured":"Tarazona N et al (2019) Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. Ann Oncol 30(11):1804\u20131812","journal-title":"Ann Oncol"},{"issue":"2","key":"3626_CR31","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","volume":"39","author":"DL Jardim","year":"2021","unstructured":"Jardim DL et al (2021) The Challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell 39(2):154\u2013173","journal-title":"Cancer Cell"},{"issue":"3","key":"3626_CR32","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2023.02.014","volume":"41","author":"C Tay","year":"2023","unstructured":"Tay C, Tanaka A, Sakaguchi S (2023) Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy. Cancer Cell 41(3):450\u2013465","journal-title":"Cancer Cell"},{"issue":"2","key":"3626_CR33","doi-asserted-by":"crossref","first-page":"e001749","DOI":"10.1136\/jitc-2020-001749","volume":"9","author":"H Van Damme","year":"2021","unstructured":"Van Damme H et al (2021) Therapeutic depletion of CCR8+ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy. J Immunother Cancer 9(2):e001749","journal-title":"J Immunother Cancer"},{"key":"3626_CR34","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aba0759","author":"JC Lee","year":"2020","unstructured":"Lee JC et al (2020) Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis. Sci Immunol. https:\/\/doi.org\/10.1126\/sciimmunol.aba0759","journal-title":"Sci Immunol"},{"issue":"8","key":"3626_CR35","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1002\/eji.201847659","volume":"49","author":"A Tanaka","year":"2019","unstructured":"Tanaka A, Sakaguchi S (2019) Targeting Treg cells in cancer immunotherapy. Eur J Immunol 49(8):1140\u20131146","journal-title":"Eur J Immunol"},{"issue":"6","key":"3626_CR36","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1111\/cas.14422","volume":"111","author":"S Suzuki","year":"2020","unstructured":"Suzuki S et al (2020) Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers. Cancer Sci 111(6):1943\u20131957","journal-title":"Cancer Sci"},{"issue":"1","key":"3626_CR37","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-020-01014-w","volume":"14","author":"S Liu","year":"2021","unstructured":"Liu S et al (2021) NK cell-based cancer immunotherapy: from basic biology to clinical development. J Hematol Oncol 14(1):7","journal-title":"J Hematol Oncol"},{"issue":"2","key":"3626_CR38","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","volume":"18","author":"JA Myers","year":"2021","unstructured":"Myers JA, Miller JS (2021) Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol 18(2):85\u2013100","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"3626_CR39","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","volume":"19","author":"N Shimasaki","year":"2020","unstructured":"Shimasaki N, Jain A, Campana D (2020) NK cells for cancer immunotherapy. Nat Rev Drug Discov 19(3):200\u2013218","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"3626_CR40","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","volume":"22","author":"TJ Laskowski","year":"2022","unstructured":"Laskowski TJ, Biederst\u00e4dt A, Rezvani K (2022) Natural killer cells in antitumour adoptive cell immunotherapy. Nat Rev Cancer 22(10):557\u2013575","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3626_CR41","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40425-018-0328-8","volume":"6","author":"PB Subrahmanyam","year":"2018","unstructured":"Subrahmanyam PB et al (2018) Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients. J Immunother Cancer 6(1):18","journal-title":"J Immunother Cancer"},{"issue":"1","key":"3626_CR42","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41423-018-0027-x","volume":"16","author":"SS Wang","year":"2019","unstructured":"Wang SS et al (2019) Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer. Cell Mol Immunol 16(1):6\u201318","journal-title":"Cell Mol Immunol"},{"issue":"22","key":"3626_CR43","doi-asserted-by":"crossref","first-page":"6075","DOI":"10.1158\/1078-0432.CCR-21-0697","volume":"27","author":"SS Kim","year":"2021","unstructured":"Kim SS et al (2021) Role of B cells in responses to checkpoint blockade immunotherapy and overall survival of cancer patients. Clin Cancer Res 27(22):6075\u20136082","journal-title":"Clin Cancer Res"},{"issue":"23","key":"3626_CR44","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1182\/blood.2021013733","volume":"139","author":"Y Qi","year":"2022","unstructured":"Qi Y et al (2022) Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL. Blood 139(23):3376\u20133386","journal-title":"Blood"},{"issue":"9","key":"3626_CR45","first-page":"1670","volume":"41","author":"T Wang","year":"2023","unstructured":"Wang T et al (2023) Coadministration of CD19 and CD22 directed chimeric antigen receptor T-cell therapy in childhood B-cell acute lymphoblastic leukemia: a single-arm, multicenter. Phase II Trial J Clin Oncol 41(9):1670\u20131683","journal-title":"Phase II Trial J Clin Oncol"},{"issue":"43","key":"3626_CR46","doi-asserted-by":"crossref","first-page":"6223","DOI":"10.1038\/s41388-021-02019-6","volume":"40","author":"X Chen","year":"2021","unstructured":"Chen X et al (2021) CD8+ T effector and immune checkpoint signatures predict prognosis and responsiveness to immunotherapy in bladder cancer. Oncogene 40(43):6223\u20136234","journal-title":"Oncogene"},{"issue":"10","key":"3626_CR47","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang P et al (2018) Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med 24(10):1550\u20131558","journal-title":"Nat Med"},{"issue":"1","key":"3626_CR48","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s12935-022-02675-y","volume":"22","author":"H Huang","year":"2022","unstructured":"Huang H et al (2022) Development and validation of a nomogram for evaluating the prognosis of immunotherapy plus antiangiogenic therapy in non-small cell lung cancer. Cancer Cell Int 22(1):261","journal-title":"Cancer Cell Int"},{"key":"3626_CR49","doi-asserted-by":"crossref","first-page":"1012673","DOI":"10.3389\/fimmu.2022.1012673","volume":"13","author":"P Chi","year":"2022","unstructured":"Chi P et al (2022) An immune risk score predicts progression-free survival of melanoma patients in South China receiving anti-PD-1 inhibitor therapy-a retrospective cohort study examining 66 circulating immune cell subsets. Front Immunol 13:1012673","journal-title":"Front Immunol"},{"key":"3626_CR50","doi-asserted-by":"crossref","first-page":"10572","DOI":"10.1038\/ncomms10572","volume":"7","author":"RP Kristjansson","year":"2016","unstructured":"Kristjansson RP et al (2016) Common and rare variants associating with serum levels of creatine kinase and lactate dehydrogenase. Nat Commun 7:10572","journal-title":"Nat Commun"},{"issue":"3","key":"3626_CR51","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41416-018-0167-x","volume":"119","author":"NB Wagner","year":"2018","unstructured":"Wagner NB et al (2018) S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies. Br J Cancer 119(3):339\u2013346","journal-title":"Br J Cancer"},{"issue":"9","key":"3626_CR52","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s00262-020-02585-w","volume":"69","author":"L Peng","year":"2020","unstructured":"Peng L et al (2020) Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors. Cancer Immunol Immunother 69(9):1813\u20131822","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"3626_CR53","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s40425-018-0383-1","volume":"6","author":"M Capone","year":"2018","unstructured":"Capone M et al (2018) Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J Immunother Cancer 6(1):74","journal-title":"J Immunother Cancer"},{"issue":"1","key":"3626_CR54","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1186\/s12935-021-02217-y","volume":"21","author":"A Zhang","year":"2021","unstructured":"Zhang A et al (2021) Dynamic serum biomarkers to predict the efficacy of PD-1 in patients with nasopharyngeal carcinoma. Cancer Cell Int 21(1):518","journal-title":"Cancer Cell Int"},{"issue":"4","key":"3626_CR55","doi-asserted-by":"crossref","first-page":"197","DOI":"10.5732\/cjc.011.10283","volume":"31","author":"G Li","year":"2012","unstructured":"Li G et al (2012) Increased pretreatment levels of serum LDH and ALP as poor prognostic factors for nasopharyngeal carcinoma. Chin J Cancer 31(4):197\u2013206","journal-title":"Chin J Cancer"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03626-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-023-03626-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03626-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T13:08:37Z","timestamp":1707570517000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-023-03626-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["3626"],"URL":"https:\/\/doi.org\/10.1007\/s00262-023-03626-w","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"20 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Ethics Committee of SYSUCC approved this study, and the approval number was B2023-621-01. Written informed consent for the use of clinical parameters and collected samples for further studies at the time of patient admission was obtained as a general standard procedure.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"14"}}